Wang Jia Wei, Zhou Min Wen, Zhang Xiulan, Huang Wen Bin, Gao Xin Bo, Wang Wei, Chen Shida, Zhang Xin Yu, Ding Xiao Yan, Jonas Jost B
Zhongshan Ophthalmic Center, State Key Laboratory of Ophthalmology, Sun Yat-Sen University, Guangzhou, China.
Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-Karls-University, Heidelberg, Germany.
Clin Exp Ophthalmol. 2015 Jul;43(5):415-21. doi: 10.1111/ceo.12477. Epub 2015 Jan 14.
This study aims to evaluate concentrations of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF)-A in aqueous of patients with neovascular glaucoma prior to, and shortly after, an intravitreal ranibizumab injection.
Interventional comparative study.
The study included patients undergoing an intravitreal ranibizumab injection about one week before anti-glaucomatous surgery (study group) or who underwent routine cataract surgery (control group).
Aqueous and blood samples were collected at the occasions of intravitreal injections, anti-glaucomatous surgery or cataract surgery. They were analysed by enzyme-linked immunosorbent assay.
Concentrations of PEDF and VEGF-A in aqueous.
At baseline, concentrations VEGF-A (3698 ± 2105 pg/mL vs. 233 ± 98 pg/mL) and PEDF (18.9 ± 11.9 ug/mL vs. 2.2 ± 0.6 ug/mL) were higher (P < 0.001) in the study group (n = 20 patients) than control group (n = 20 patients). The VEGF-A/PEDF concentration ratio was higher in the study group (396 ± 554 vs. 110 ± 49; P = 0.02). One week after the ranibizumab injection, iris neovascularization had completely regressed in 17 (85%) eyes, and VEGF-A concentration decreased significantly (P < 0.001) to 184 ± 130 pg/mL. The PEDF concentration remained unchanged (19 ± 12 ug/mL). The VEGF-A/PEDF concentration ratio decreased to 13.2 ± 13.6. Plasma concentrations of VEGF-A and PEDF did not differ significantly between both groups (P = 0.65 and P = 0.15, respectively) nor were they significantly correlated with the aqueous concentrations (all P > 0.15).
Aqueous concentrations of VEGF-A and PEDF were significantly elevated in eyes with neovascular glaucoma. Within one week after intravitreal injection of ranibizumab, VEGF-A concentration decreased to subnormal levels, while the PEDF concentration remained unchanged and the VEGF-A/PEDF ratio decreased.
本研究旨在评估玻璃体内注射雷珠单抗之前及之后不久，新生血管性青光眼患者房水中色素上皮衍生因子（PEDF）和血管内皮生长因子（VEGF）-A的浓度。
干预性对比研究。
本研究纳入了在抗青光眼手术前约一周接受玻璃体内注射雷珠单抗的患者（研究组）或接受常规白内障手术的患者（对照组）。
在玻璃体内注射、抗青光眼手术或白内障手术时采集房水和血液样本。通过酶联免疫吸附测定法对其进行分析。
房水中PEDF和VEGF-A的浓度。
在基线时，研究组（20例患者）的VEGF-A（3698±2105 pg/mL对233±98 pg/mL）和PEDF（18.9±11.9μg/mL对2.2±0.6μg/mL）浓度高于对照组（20例患者）（P<0.001）。研究组的VEGF-A/PEDF浓度比更高（396±554对110±49；P=0.02）。雷珠单抗注射一周后，17只眼（85%）的虹膜新生血管完全消退，VEGF-A浓度显著降低（P<0.001）至184±130 pg/mL。PEDF浓度保持不变（19±12μg/mL）。VEGF-A/PEDF浓度比降至13.2±13.6。两组间VEGF-A和PEDF的血浆浓度无显著差异（分别为P=0.65和P=0.15），且它们与房水浓度也无显著相关性（所有P>0.15）。
新生血管性青光眼患者房水中VEGF-A和PEDF的浓度显著升高。玻璃体内注射雷珠单抗后一周内，VEGF-A浓度降至正常水平以下，而PEDF浓度保持不变，VEGF-A/PEDF比值降低。
